Journal
FRONTIERS IN PHARMACOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.554961
Keywords
metabolic sydrome; polypharmacology; multi-target drug; peroxisome prolifer ators-activated receptor-γ soluble epoxide hydrolase; farnesoid X receptor
Categories
Funding
- German Research Foundation (DFG) [PR1405/7-1, SFB 1039]
- National Institute of Health (NIH) [DK103616]
- Ralph and Marian Falk Medical Research Trust Bank of America, N.A. Trustee grant
Ask authors/readers for more resources
Metabolic syndrome requires polypharmacological treatment, however, complex treatment regimens often lead to drug-drug interactions and poor patient adherence. Multi-target approaches aim at reducing polypharmacology and improving efficacy.
Metabolic syndrome (MetS) is a highly prevalent disease cluster worldwide. It requires polypharmacological treatment of the single conditions including type II diabetes, hypertension, and dyslipidemia, as well as the associated comorbidities. The complex treatment regimens with various drugs lead to drug-drug interactions and inadequate patient adherence, resulting in poor management of the disease. Multi-target approaches aim at reducing the polypharmacology and improving the efficacy. This review summarizes the medicinal chemistry efforts to develop multi-target ligands for MetS. Different combinations of pharmacological targets in context of in vivo efficacy and future perspective for multi-target drugs in MetS are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available